Skip to main content
Top
Published in: Annals of Surgical Oncology 11/2014

01-10-2014 | Hepatobiliary Tumors

Identification of Risk and Prognostic Factors for Patients with Clonorchiasis-Associated Intrahepatic Cholangiocarcinoma

Authors: Guo-Wei Zhang, MD, PhD, Jian-Hua Lin, MD, PhD, Jian-Ping Qian, MD, PhD, Jie Zhou, MD, PhD

Published in: Annals of Surgical Oncology | Issue 11/2014

Login to get access

Abstract

Background

Intrahepatic cholangiocarcinoma caused by clonorchiasis (CICC) has a poor prognosis, and there have been insufficient studies regarding risk and prognostic factors. We aimed to identify CICC-associated factors.

Methods

A retrospective analysis of 127 eligible patients with CICC was performed with 254 clonorchiasis cases used as matched controls to identify risk factors for CICC. The main outcomes analyzed included overall survival (OS) and disease-free survival (DFS).

Results

Out of 127 surgeries, R0 resection was performed in 61 patients, R1 in 32 patients, and R2 in 22 patients; nonresection surgery was performed in 12 patients. Median OS for the entire cohort was 29.5 months. Median OS and DFS for 61 patients with R0 resection were 52.4 months and 41.5 months, respectively. We found independent risk factors for CICC were duration of raw fish consumption of ≥28 years (p < 0.001) and hepatitis B virus infection (p = 0.040). R0 resection (p < 0.001), well or moderately differentiated tumor (p = 0.019), and stage I to II tumor (p < 0.001) predicted improved OS for CICC. Serum carcinoembryonic antigen level of ≤5 ng/ml (p = 0.029) and stage I to II tumor (p < 0.001) predicted improved DFS.

Conclusions

Duration of raw fish consumption ≥28 years and hepatitis B virus infection were significant risk factors for CICC in patients with clonorchiasis. For patients with CICC, curative resection is an effective treatment. Higher tumor differentiation and earlier American Joint Committee on Cancer stage predicted good prognosis. Serum carcinoembryonic antigen level was found to predict the possibility of recurrence after curative resection.
Literature
2.
go back to reference Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology. 2001;33:1353–7.PubMedCrossRef Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology. 2001;33:1353–7.PubMedCrossRef
3.
go back to reference Bertuccio P, Bosetti C, Levi F, Decarli A, Negri E, La Vecchia C. A comparison of trends in mortality from primary liver cancer and intrahepatic cholangiocarcinoma in Europe. Ann Oncol. 2013;24:1667–74.PubMedCrossRef Bertuccio P, Bosetti C, Levi F, Decarli A, Negri E, La Vecchia C. A comparison of trends in mortality from primary liver cancer and intrahepatic cholangiocarcinoma in Europe. Ann Oncol. 2013;24:1667–74.PubMedCrossRef
4.
go back to reference de Martel C, Plummer M, Franceschi S. Cholangiocarcinoma: descriptive epidemiology and risk factors. Gastroenterol Clin Biol. 2010;34:173–80.PubMedCrossRef de Martel C, Plummer M, Franceschi S. Cholangiocarcinoma: descriptive epidemiology and risk factors. Gastroenterol Clin Biol. 2010;34:173–80.PubMedCrossRef
5.
6.
go back to reference Pitaksakulrat O, Sithithaworn P, Laoprom N, Laha T, Petney TN, Andrews RH. A cross-sectional study on the potential transmission of the carcinogenic liver fluke Opisthorchis viverrini and other fishborne zoonotic trematodes by aquaculture fish. Foodborne Pathog Dis. 2013;10:35–41.PubMedCrossRef Pitaksakulrat O, Sithithaworn P, Laoprom N, Laha T, Petney TN, Andrews RH. A cross-sectional study on the potential transmission of the carcinogenic liver fluke Opisthorchis viverrini and other fishborne zoonotic trematodes by aquaculture fish. Foodborne Pathog Dis. 2013;10:35–41.PubMedCrossRef
7.
go back to reference Fürst T, Keiser J, Utzinger J. Global burden of human food-borne trematodiasis: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12:210–21.PubMedCrossRef Fürst T, Keiser J, Utzinger J. Global burden of human food-borne trematodiasis: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12:210–21.PubMedCrossRef
8.
go back to reference Fang YY. Epidemiologic characteristics of Clonorchiasis sinensis in Guandong province, China. Southeast Asian J Trop Med Public Health. 1994;25:291–5.PubMed Fang YY. Epidemiologic characteristics of Clonorchiasis sinensis in Guandong province, China. Southeast Asian J Trop Med Public Health. 1994;25:291–5.PubMed
10.
go back to reference Dhanasekaran R, Hemming AW, Zendejas I, et al. Treatment outcomes and prognostic factors of intrahepatic cholangiocarcinoma. Oncol Rep. 2013;29:1259–67.PubMedPubMedCentral Dhanasekaran R, Hemming AW, Zendejas I, et al. Treatment outcomes and prognostic factors of intrahepatic cholangiocarcinoma. Oncol Rep. 2013;29:1259–67.PubMedPubMedCentral
11.
go back to reference Zhou XD, Tang ZY, Fan J, et al. Intrahepatic cholangiocarcinoma: report of 272 patients compared with 5,829 patients with hepatocellular carcinoma. J Cancer Res Clin Oncol. 2009;135:1073–80.PubMedCrossRef Zhou XD, Tang ZY, Fan J, et al. Intrahepatic cholangiocarcinoma: report of 272 patients compared with 5,829 patients with hepatocellular carcinoma. J Cancer Res Clin Oncol. 2009;135:1073–80.PubMedCrossRef
12.
go back to reference Stagg RJ. Intrahepatic cholangiocarcinoma. In: Helms RA, Quan DJ, editors. Textbook of therapeutics: drug and disease management. 8th ed. Philadelphia: Lippincott Williams & Wilkins; 2006. p. 2380. Stagg RJ. Intrahepatic cholangiocarcinoma. In: Helms RA, Quan DJ, editors. Textbook of therapeutics: drug and disease management. 8th ed. Philadelphia: Lippincott Williams & Wilkins; 2006. p. 2380.
13.
go back to reference Samaras V, Rafailidis PI, Mourtzoukou EG, Peppas G, Falagas ME. Chronic bacterial and parasitic infections and cancer: a review. J Infect Dev Ctries. 2010;4:267–81.PubMed Samaras V, Rafailidis PI, Mourtzoukou EG, Peppas G, Falagas ME. Chronic bacterial and parasitic infections and cancer: a review. J Infect Dev Ctries. 2010;4:267–81.PubMed
14.
go back to reference Srivatanakul P, Sriplung H, Deerasamee S. Epidemiology of liver cancer: an overview. Asian Pac J Cancer Prev. 2004;5:118–25.PubMed Srivatanakul P, Sriplung H, Deerasamee S. Epidemiology of liver cancer: an overview. Asian Pac J Cancer Prev. 2004;5:118–25.PubMed
16.
go back to reference Sripa B, Brindley PJ, Mulvenna J, et al. The tumorigenic liver fluke Opisthorchis viverrini—multiple pathways to cancer. Trends Parasitol. 2012;28:395–407.PubMedCrossRefPubMedCentral Sripa B, Brindley PJ, Mulvenna J, et al. The tumorigenic liver fluke Opisthorchis viverrini—multiple pathways to cancer. Trends Parasitol. 2012;28:395–407.PubMedCrossRefPubMedCentral
17.
go back to reference Wu Q, He XD, Yu L, Liu W, Tao LY. The metabolic syndrome and risk factors for biliary tract cancer: a case-control study in China. Asian Pac J Cancer Prev. 2012;13:1963–9.PubMedCrossRef Wu Q, He XD, Yu L, Liu W, Tao LY. The metabolic syndrome and risk factors for biliary tract cancer: a case-control study in China. Asian Pac J Cancer Prev. 2012;13:1963–9.PubMedCrossRef
18.
go back to reference Peng NF, Li LQ, Qin X, et al. Evaluation of risk factors and clinicopathologic features for intrahepatic cholangiocarcinoma in Southern China: a possible role of hepatitis B virus. Ann Surg Oncol. 2011;18:1258–66.PubMedCrossRef Peng NF, Li LQ, Qin X, et al. Evaluation of risk factors and clinicopathologic features for intrahepatic cholangiocarcinoma in Southern China: a possible role of hepatitis B virus. Ann Surg Oncol. 2011;18:1258–66.PubMedCrossRef
19.
go back to reference Yamamoto M, Ariizumi S. Surgical outcomes of intrahepatic cholangiocarcinoma. Surg Today. 2011;41:896–902.PubMedCrossRef Yamamoto M, Ariizumi S. Surgical outcomes of intrahepatic cholangiocarcinoma. Surg Today. 2011;41:896–902.PubMedCrossRef
20.
go back to reference Shimada K, Sano T, Sakamoto Y, Esaki M, Kosuge T, Ojima H. Clinical impact of the surgical margin status in hepatectomy for solitary mass-forming type intrahepatic cholangiocarcinoma without lymph node metastases. J Surg Oncol. 2007;96:160–5.PubMedCrossRef Shimada K, Sano T, Sakamoto Y, Esaki M, Kosuge T, Ojima H. Clinical impact of the surgical margin status in hepatectomy for solitary mass-forming type intrahepatic cholangiocarcinoma without lymph node metastases. J Surg Oncol. 2007;96:160–5.PubMedCrossRef
21.
go back to reference Witzigmann H, Berr F, Ringel U, et al. Surgical and palliative management and outcome in 184 patients with hilar cholangiocarcinoma: palliative photodynamic therapy plus stenting is comparable to r1/r2 resection. Ann Surg. 2006;244:230–9.PubMedCrossRefPubMedCentral Witzigmann H, Berr F, Ringel U, et al. Surgical and palliative management and outcome in 184 patients with hilar cholangiocarcinoma: palliative photodynamic therapy plus stenting is comparable to r1/r2 resection. Ann Surg. 2006;244:230–9.PubMedCrossRefPubMedCentral
22.
go back to reference He XR, Wu XP. Difference in biological characteristics and sensitivity to chemotherapy and radiotherapy between intrahepatic and extrahepatic cholangiocarcinoma cells in vitro. Chin Med Sci J. 2008;23:54–9.PubMedCrossRef He XR, Wu XP. Difference in biological characteristics and sensitivity to chemotherapy and radiotherapy between intrahepatic and extrahepatic cholangiocarcinoma cells in vitro. Chin Med Sci J. 2008;23:54–9.PubMedCrossRef
23.
go back to reference Petrowsky H, Hong JC. Current surgical management of hilar and intrahepatic cholangiocarcinoma: the role of resection and orthotopic liver transplantation. Transplant Proc. 2009;41:4023–35.PubMedCrossRef Petrowsky H, Hong JC. Current surgical management of hilar and intrahepatic cholangiocarcinoma: the role of resection and orthotopic liver transplantation. Transplant Proc. 2009;41:4023–35.PubMedCrossRef
25.
go back to reference Horgan AM, Amir E, Walter T, Knox JJ. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J Clin Oncol. 2012;30:1934–40.PubMedCrossRef Horgan AM, Amir E, Walter T, Knox JJ. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J Clin Oncol. 2012;30:1934–40.PubMedCrossRef
26.
go back to reference Fisher SB, Patel SH, Kooby DA, et al. Lymphovascular and perineural invasion as selection criteria for adjuvant therapy in intrahepatic cholangiocarcinoma: a multi-institution analysis. HPB (Oxford). 2012;14:514–22.PubMedCrossRefPubMedCentral Fisher SB, Patel SH, Kooby DA, et al. Lymphovascular and perineural invasion as selection criteria for adjuvant therapy in intrahepatic cholangiocarcinoma: a multi-institution analysis. HPB (Oxford). 2012;14:514–22.PubMedCrossRefPubMedCentral
27.
go back to reference Li T, Qin LX, Zhou J, et al. Staging, prognostic factors and adjuvant therapy of intrahepatic cholangiocarcinoma after curative resection. Liver Int. 2013. doi: 10.1111/liv.12364 Li T, Qin LX, Zhou J, et al. Staging, prognostic factors and adjuvant therapy of intrahepatic cholangiocarcinoma after curative resection. Liver Int. 2013. doi: 10.​1111/​liv.​12364
28.
go back to reference Arrington AK, Nelson RA, Falor A, et al. Impact of medical and surgical intervention on survival in patients with cholangiocarcinoma. World J Gastrointest Surg. 2013;5:178–86.PubMedCrossRefPubMedCentral Arrington AK, Nelson RA, Falor A, et al. Impact of medical and surgical intervention on survival in patients with cholangiocarcinoma. World J Gastrointest Surg. 2013;5:178–86.PubMedCrossRefPubMedCentral
29.
go back to reference Farges O, Fuks D, Le Treut YP, et al. AJCC 7th edition of TNM staging accurately discriminates outcomes of patients with resectable intrahepatic cholangiocarcinoma: by the FC-IHCC-2009 study group. Cancer. 2011;117:2170–7.PubMedCrossRef Farges O, Fuks D, Le Treut YP, et al. AJCC 7th edition of TNM staging accurately discriminates outcomes of patients with resectable intrahepatic cholangiocarcinoma: by the FC-IHCC-2009 study group. Cancer. 2011;117:2170–7.PubMedCrossRef
30.
go back to reference Yamashita Y, Taketomi A, Morita K, et al. The impact of surgical treatment and poor prognostic factors for patients with intrahepatic cholangiocarcinoma: retrospective analysis of 60 patients. Anticancer Res. 2008;28:2353–9.PubMed Yamashita Y, Taketomi A, Morita K, et al. The impact of surgical treatment and poor prognostic factors for patients with intrahepatic cholangiocarcinoma: retrospective analysis of 60 patients. Anticancer Res. 2008;28:2353–9.PubMed
31.
32.
go back to reference Sulpice L, Rayar M, Boucher E, Pracht M, Meunier B, Boudjema K. Treatment of recurrent intrahepatic cholangiocarcinoma. Br J Surg. 2012;99:1711–7.PubMedCrossRef Sulpice L, Rayar M, Boucher E, Pracht M, Meunier B, Boudjema K. Treatment of recurrent intrahepatic cholangiocarcinoma. Br J Surg. 2012;99:1711–7.PubMedCrossRef
33.
go back to reference Malaguarnera G, Paladina I, Giordano M, Malaguarnera M, Bertino G, Berretta M. Serum markers of intrahepatic cholangiocarcinoma. Dis Markers. 2013;34:219–28.PubMedCrossRefPubMedCentral Malaguarnera G, Paladina I, Giordano M, Malaguarnera M, Bertino G, Berretta M. Serum markers of intrahepatic cholangiocarcinoma. Dis Markers. 2013;34:219–28.PubMedCrossRefPubMedCentral
34.
go back to reference Nanashima A, Sumida Y, Abo T, et al. Patient outcome and prognostic factors in intrahepatic cholangiocarcinoma after hepatectomy. Hepatogastroenterology. 2007;54:2337–42.PubMed Nanashima A, Sumida Y, Abo T, et al. Patient outcome and prognostic factors in intrahepatic cholangiocarcinoma after hepatectomy. Hepatogastroenterology. 2007;54:2337–42.PubMed
35.
go back to reference Saxena A, Chua TC, Sarkar A, Chu F, Morris DL. Clinicopathologic and treatment-related factors influencing recurrence and survival after hepatic resection of intrahepatic cholangiocarcinoma: a 19-year experience from an established Australian hepatobiliary unit. J Gastrointest Surg. 2010;14:1128–38.PubMedCrossRef Saxena A, Chua TC, Sarkar A, Chu F, Morris DL. Clinicopathologic and treatment-related factors influencing recurrence and survival after hepatic resection of intrahepatic cholangiocarcinoma: a 19-year experience from an established Australian hepatobiliary unit. J Gastrointest Surg. 2010;14:1128–38.PubMedCrossRef
36.
go back to reference Uenishi T, Yamazaki O, Tanaka H, et al. Serum cytokeratin 19 fragment (CYFRA21-1) as a prognostic factor in intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2008;15:583–9.PubMedCrossRef Uenishi T, Yamazaki O, Tanaka H, et al. Serum cytokeratin 19 fragment (CYFRA21-1) as a prognostic factor in intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2008;15:583–9.PubMedCrossRef
Metadata
Title
Identification of Risk and Prognostic Factors for Patients with Clonorchiasis-Associated Intrahepatic Cholangiocarcinoma
Authors
Guo-Wei Zhang, MD, PhD
Jian-Hua Lin, MD, PhD
Jian-Ping Qian, MD, PhD
Jie Zhou, MD, PhD
Publication date
01-10-2014
Publisher
Springer US
Published in
Annals of Surgical Oncology / Issue 11/2014
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-014-3710-x

Other articles of this Issue 11/2014

Annals of Surgical Oncology 11/2014 Go to the issue